| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.0024 | 1 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.0009 | 1 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-06 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-06 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-06 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-06 |